Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11576865 Sustained-release dosage forms of ruxolitinib

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Date Filed
June 23, 2022
Date of Patent
February 14, 2023
Patent Application Number
17847760
Patent Citations
‌
US Patent 10513522 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
‌
US Patent 10561616 Sustained release dosage forms for a JAK1 inhibitor
‌
US Patent 10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
‌
US Patent 10640506 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
‌
US Patent 10695337 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
‌
US Patent 10766900 Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
‌
US Patent 10874616 Sustained-release dosage forms of ruxolitinib
‌
US Patent 11045421 Sustained release dosage forms for a JAK1 inhibitor
‌
US Patent 11214573 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
‌
US Patent 11331320 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11576865
Patent Primary Examiner
‌
Umamaheswari Ramachandran
CPC Code
‌
A61K 9/2054
‌
A61K 31/519

Find more entities like US Patent 11576865 Sustained-release dosage forms of ruxolitinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.